checkmate 648: novel treatment for patients with advanced esophageal squamous cell carcinoma
Published 2 years ago • 416 plays • Length 3:05Download video MP4
Download video MP3
Similar videos
-
4:59
checkmate 648: 1l io-io in advanced esophageal squamous cell carcinoma
-
1:01
long-term efficacy of nivolumab combinations in advanced escc in checkmate 648
-
1:19
29-month follow-up from checkmate 648: nivolumab combination therapy in escc
-
0:37
45-month checkmate 648 results show nivolumab combos' sustained benefits in escc
-
2:10
checkmate 648: nivo chemo or ipi vs chemo as 1l treatment for advanced escc
-
4:51
expanded efficacy and safety analyses from checkmate 648
-
1:43
biomarker-driven treatments for esophageal squamous cell carcinoma
-
2:10
biomarker analyses from checkmate 648
-
9:32
checkmate 648: nivolumab plus ipilimumab or nivo plus chemo versus chemo as (1l) treatment for a...
-
4:29
advances in adjuvant and 1l immune checkpoint blockade for gastric and esophageal cancer
-
11:36
emerging data with immunotherapy in esophageal squamous cell carcinoma
-
3:02
novel treatment options for patients with metastatic, inoperable urothelial carcinomas
-
10:45
new data on adjuvant treatment of esophageal cancer
-
5:20
nivolumab vs chemotherapy for advanced esophageal squamous cell carcinoma
-
2:14
standard-of-care and future research directions for advanced squamous cell carcinoma
-
18:59
controversy debate 2: selecting optimal treatments for esophagus cancer - whom to operate upon?
-
1:08
novel approaches in treating merkel cell carcinoma
-
6:23
checkmate 649 3-year follow-up: nivolumab plus chemotherapy for gastric and esophageal cancers
-
24:25
emerging data with immunotherapy in esophageal squamous cell carcinoma& impact for clinical practice